AnaSed (100 mg/mL) (Canada)This page contains information on AnaSed (100 mg/mL) for veterinary use.
The information provided typically includes the following:
- AnaSed (100 mg/mL) Indications
- Warnings and cautions for AnaSed (100 mg/mL)
- Direction and dosage information for AnaSed (100 mg/mL)
AnaSed (100 mg/mL)This treatment applies to the following species:
Net Contents: 50 mL
Veterinary Use Only
Xylazine Injection 100 mg/mL
(as xylazine hydrochloride)
Analgesic and Sedative for Use in Horses
AnaSed is supplied in 50 mL multiple-dose vials as a sterile solution.
Each mL contains: medicinal ingredient xylazine (as hydrochloride) 100 mg; and the following nonmedicinal ingredients: 0.9 mg methylparaben, 0.1 mg propylparaben, 5.0 mg sodium citrate dihydrate and water for injection. The pH is adjusted with hydrochloric acid.
Xylazine, a non-narcotic compound, is an analgesic and sedative as well as a muscle relaxant. Its analgesic and sedative activity is related to central nervous system depression. Its muscle-relaxant effect is based on inhibition of the intraneural transmission of impulses in the central nervous system. The principal pharmacological activities develop within 10 to 15 minutes after intramuscular injection, and within three to five minutes following intravenous administration.
A sleep-like state, the depth of which is dose-dependent, is usually maintained for one to two hours, while analgesia lasts from 15 to 30 minutes. The centrally-acting muscle relaxant effect causes relaxation of the skeletal musculature, complementing sedation and analgesia.
In animals under the influence of AnaSed the respiratory rate is reduced as in natural sleep. Following treatment with AnaSed, the heart rate is decreased and a transient change in the conductivity of the cardiac muscle may occur, as evidenced by a partial atrioventricular block. This resembles the atrioventricular block often observed in normal horses.1,2,3,4
Although a partial A-V block may occasionally occur following intramuscular injection of AnaSed, the incidence is less than when it is administered intravenously. Intravenous administration of AnaSed causes a transient rise in blood pressure, followed by a slight decrease.
AnaSed has no effect on blood clotting time or other hematologic parameters.
AnaSed (100 mg/mL) Indications
AnaSed should be used in horses when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. It has been used successfully as follows:
1. Diagnostic procedures - oral and ophthalmic examinations, abdominal palpation, rectal palpation, vaginal examination, catheterization of the bladder and radiographic examinations.
2. Orthopedic procedures, such as the application of casting materials and splints.
3. Dental procedures.
4. Minor surgical procedures of short duration such as debridement, removal of cutaneous neoplasms and suturing of lacerations.
5. To calm and facilitate the handling of fractious animals.
6. Therapeutic medication for sedation and relief of pain following injury or surgery.
7. Major surgical procedures:
a. When used as a pre-anesthetic to general anesthesia.
b. When used in conjunction with local anesthetics.
Doses in excess of those recommended should not be given. While xylazine is tolerated in horses at five times the recommended dose, it may produce convulsions and long periods of sedation.
Dosage and Administration
Intravenous - 0.5 mL/45 kg of body weight (1.1 mg/kg).
Intramuscular - 1.0 mL/45 kg of body weight (2.2 mg/kg).
Following the injection of AnaSed, the animal should be allowed to rest quietly until the full effect has been reached.
These dosages produce sedation which is usually maintained for one (1) to two (2) hours and an analgesia which lasts for 15 to 30 minutes.
2. Pre-anesthetic to Local Anesthesia: AnaSed at the recommended dosages can be used in conjunction with local anesthetics, such as procaine or lidocaine.
3. Pre-anesthetic to General Anesthesia: AnaSed, at the recommended dosage rates, produces an additive effect to central nervous system depressants such as pentobarbital sodium, thiopental sodium and thiamylal sodium. Therefore, the dosage of such compounds should be reduced and administered to the desired effect. In general, only one-third (1/3) to one-half (1/2) of the calculated dosage of the barbiturates will be needed to produce a surgical plane of anesthesia. Postanaesthetic or emergence excitement has not been observed in animals pre-anaesthetized with AnaSed.
AnaSed has been used successfully as a pre-anesthetic agent for pentobarbital sodium, thiopental sodium, thiamylal sodium, nitrous oxide, ether, halothane, glyceryl guaiacolate and methoxyflurane anesthesia.
Side EffectsAnaSed used at the recommended dosage levels may occasionally cause slight muscle tremors, bradycardia with partial A-V heart block and a reduced respiratory rate. Movement in response to sharp auditory stimuli may be observed. Sweating, rarely profuse, has been reported following administration.
PrecautionsCareful consideration should be given before administering the product to horses with significantly depressed respiration, severe pathologic heart disease, advanced liver or kidney disease, severe endotoxic or traumatic shock and stress conditions such as extreme heat, cold, high altitude or fatigue.
Do not use AnaSed in conjunction with tranquilizers.
Since an additive effect results from the use of AnaSed and the barbiturate compounds, it should be used with caution with these central nervous system depressants. Products known to produce respiratory depression or apnea, such as thiamylal sodium, should be given at a reduced dosage and, when injected intravenously, should be administered slowly. When intravenous administration is desired, avoid perivascular injection in order to achieve the desired effect.
Intracarotid arterial injection should be avoided. As with many compounds, including tranquilizers, immediate violent seizures followed by collapse may result from inadvertent administration into the carotid artery. Although the reaction with AnaSed is usually transient and recovery may be rapid and complete, special care should be taken to assure that the needle is in the jugular vein rather than the carotid artery.
Bradycardia and an arrhythmia in the form of incomplete atrioventricular block have been reported following AnaSed administration. Although clinically the importance of this effect is questioned,1,2,3,4 a standard dose of atropine given prior to, or following AnaSed will greatly decrease the incidence.
The analgesic effect is variable, and the depth should be carefully assayed prior to surgical/clinical procedures. The variability of analgesia occurs most frequently at the distal extremities of the horse. In spite of sedation, the practitioner and handlers should proceed with caution since defense reactions may not be diminished.
Sedation for transport is most successful if actual transportation is begun after the full effect of the drug has been reached and the animal’s stability is maintained while standing. In addition, it should be noted that animals under the influence of AnaSed can be aroused by noise or other stimuli and this may increase the risk of injury.
WarningsThis drug should not be administered to horses that are to be slaughtered for use in food.
1. Detweiller DK. The diagnosis and significance of cardiac arrhythmias. In: Catcott EJ, Smithcors JF, eds. Progress in equine practice. Wheaton, IL: American Veterinary Publications, Inc, 1966; 280-281.
2. Glazier DB. Atrioventricular heart block. Irish Vet J. 1958;12:194-198.
3. Holmes JR, Alps BJ. Observations on partial atrio-ventricular heart block in the horse. Can Vet J 1966;7:280-290.
4. Smetzer DL, Smith CR, Senta T. Second-degree atrioventricular block in the horse. Am J Vet Res 1969;30:933-946.
Akorn Animal Health, Inc., 1925 W. Field Court, Suite 300, Lake Forest, IL USA 60045
Imported & distributed by: Veterinary Healthcare Solutions, 2516 Binder Crescent, Oldcastle ON N0R 1L0
CXYA0N Rev. 09/15
CXYBAL Rev. 09/15
|Every effort has been made to ensure the accuracy of the AnaSed (100 mg/mL) information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-01-09